DO ANALYSTS LIKE OR DISLIKE CATALYST PHARMACEUTICALS, INC. (CPRX) AND EXACT SCIENCES CORPORATION (EXAS)

Looking at top Wall Street opinions, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) has recently made its way into the research list of Cantor Fitzgerald  signaling that their analyst’s rating adjustment is noteworthy. This stock was Overweight in the eyes of Cantor Fitzgerald, as reported on Friday, September 21st, 2018. Another heavy-hitting research note was published by Piper Jaffray on Friday September 7th, 2018, with this firm Resumed CPRX to an updated rating of Overweight. In the past six months and three months of trading, shares of Catalyst Pharmaceuticals, Inc. (CPRX) have moved by 53.11% and 122.13%, respectively. Brokerage Updates Related to Catalyst Pharmaceuticals, Inc. (CPRX) Stock Not a Single analyst have given underperform rating or sell rating, and 1 have given a rating of Buy or better. Based on the 6 stock market experts following this company, the average 12-month price target is $8.58. Moreover, individual price targets range between $7.00-$10.00. With its recent move to $8.50, we can see that these firms project this stock will gain by 128.69% in one year. Updates from Catalyst Pharmaceuticals, Inc. (CPRX) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 5.40% rise since the beginning of the calendar year. A Director at Catalyst Pharmaceuticals, Inc. (CPRX) bought some of its shares in a transaction that was finalized on Dec 27. Similarly, MCENANY PATRICK J bought 20,000 shares of the organization’s stock at $2.24 apiece and racked up $44,800 in earnings from the purchase. Now, MCENANY PATRICK J holds 4,737,693 shares of the company following the exchange. A Director of the organization named O’Keeffe Charles B, was engaged in a transaction that occurred on Dec 14 that managed to be worth $50,000 from the purchase of 20,000 common shares at a price of $2.50 per individual share.